Overview
Overview
Glucose-responsive insulin-secreting cells derived from UCT-WJ-MSCs through pancreatic endoderm differentiation; designed for Type 1 and Type 2 diabetes management
FOR RESEARCH USE AND INTERNATIONAL USE ONLY | Not for clinical use in the United States
| Source & Manufacturing |
|---|
| Derived from P2 UCT-WJ-MSCs via multistep pancreatic differentiation |
| Activin-A (definitive endoderm), FGF10 KAAD-cyclopamine (pancreatic progenitor), Nicotinamide Exendin-4 (islet maturation) |
| DMSO-free cryopreservation |
| Post-thaw viability 95% |
| Markers: Insulin⁺, C-peptide⁺, PDX1⁺, NKX6.1⁺, PAX4⁺ |
| Glucose-stimulated insulin secretion (GSIS) confirmed by ELISA prior to release |
| MSC priming infusion recommended prior to beta cell delivery in autoimmune T1DM to establish immune tolerance. |
Clinical Overview
Clinical Overview
Akira Pancreatic Beta Cells offer a cell-based approach to restoring physiological glucose regulation in insulin-dependent diabetes. Unlike islet transplantation (which requires cadaveric donors and lifelong immunosuppression), UCT-MSC-derived beta cells carry an immune-privileged phenotype that reduces — though does not eliminate — the risk of autoimmune destruction in T1DM. They respond to glucose concentration with insulin secretion that mimics pancreatic β-cell physiology, and their paracrine secretome (including VEGF for islet revascularization and HGF for islet regeneration) supports endogenous beta cell recovery. A 2021 RCT of UC-MSC therapy in T1DM (n=53; 27 MSC-treated) showed 40.7% clinical remission and 3 cases of complete insulin independence — demonstrating that even without full beta cell differentiation, the UCT-MSC paracrine effect alone can preserve remaining beta cell mass significantly.[1] With differentiated beta cells, insulin output potential is substantially amplified.
Process
Mechanism of Action
Glucose-Stimulated Insulin Secretion (GSIS): PDX1+ / NKX6.1+ beta cells sense extracellular glucose via GLUT2 transporter and glucokinase, generate ATP, close K-ATP channels, depolarize, and trigger Ca²⁺ influx → insulin granule exocytosis. GSIS confirmed in culture at 2.2 mM vs 22.2 mM glucose concentrations.
Paracrine Islet Support: VEGF-A secretion drives revascularization of the pancreatic microenvironment; HGF activates Met receptor on remaining host beta cells, promoting regenerative proliferation. IL-10 and TGF-β provide localized immunosuppression to protect transplanted cells from autoimmune attack.
Islet Architecture Support: Transplanted beta cells secrete fibronectin, laminin, and collagen IV, contributing to pseudo-islet formation and self-organization. In combination with endothelial cells, 3D pseudo-islet structures with improved GSIS function vs monolayer culture are achievable.
C-Peptide as Functional Marker: Co-secreted with insulin in equimolar amounts from the proinsulin cleavage. C-peptide positivity in patient serum post-transplantation is the gold-standard biomarker for engraftment and functional beta cell survival.
T-regulatory Cell Expansion: MSC-inherited immunomodulatory capacity expands Foxp3+ Tregs in the islet microenvironment, creating tolerance to transplanted cells and reducing destructive autoimmune infiltration in T1DM.
Biomarkers
Key Biomarkers & Molecular Cargo
| Marker / Molecule | Functional Role |
|---|---|
| PDX1 (Pancreatic-Duodenal Homeobox 1 | Master beta cell transcription factor; critical for insulin gene expression |
| NKX6.1 | Beta cell specification; discriminates β from δ/α lineages |
| Insulin / C-peptide | Functional markers; GSIS confirms therapeutic competence |
| PAX4 | Promotes beta cell fate over alpha cell fate during differentiation |
| GLUT2 / Glucokinase | Glucose sensing machinery; glucose metabolism triggers insulin release |
| VEGF-A / HGF | Paracrine support for islet revascularization and endogenous beta cell regeneration |
| IL-10 / TGF-β / Foxp3+ Tregs | Local immunomodulation to protect transplanted cells from autoimmune destruction |
Applications
Therapeutic Applications
- Type 1 Diabetes Mellitus — beta cell replacement (requires prior MSC immune priming infusion)
- Type 2 Diabetes — advanced insulin dependency, beta cell exhaustion, islet dysfunction
- Maturity Onset Diabetes of the Young (MODY) — monogenic beta cell dysfunction
- Islet Cell Dysfunction Post-Pancreatitis — chronic pancreatitis with beta cell loss
- Diabetic Nephropathy — beta cell UCT-MSC combination for metabolic and renal protection
- Insulin Resistance — combined with UCT-MSC therapy for systemic metabolic reset
- Hypoglycemia Unawareness — restore regulated insulin secretion
Evidence
Clinical & Preclinical Evidence
The landmark 2021 RCT (ChiCTR2100045434, n=53; 27 MSC-treated, 26 controls) of repeated IV UC-MSC infusion demonstrated 40.7% clinical remission (defined as ≥10% increase in C-peptide) at 1 year, with 3 subjects achieving complete insulin independence for 3–12 months. Multivariable analysis showed higher MSC dose correlated with remission probability. No severe adverse events.[1]
A comparative study of UC-MSCs vs BM-MSCs in T1DM (NOD mice human cohort, n=28 patients, 1-year follow-up) showed both sources significantly reduced HbA1c and insulin dose vs insulin-only therapy, with UC-MSCs demonstrating marginally superior beta cell preservation based on C-peptide trajectory.[2]
A Phase II/III clinical trial (NCT06951074, Ain Shams University) is actively recruiting to evaluate autologous insulin-producing MSC transplantation in youth with T1DM — demonstrating global clinical momentum for this approach.[3] An earlier Phase I/II trial (NCT01374854) of IV UC-MSC infusion in adult T1DM patients established safety and tolerability, providing regulatory precedent for escalating to pivotal trials.[4]
In diabetic animal models, UCT-MSC-derived beta cells engrafted into pancreatic tissue, restored blood glucose to normoglycemia within 2–3 weeks, increased serum insulin by 3–5 fold, and reduced HbA1c by 2.4% at 8 weeks — with islet morphology showing organized pseudo-islet formation and VEGF-driven revascularization.
A 2025 review (MDPI IJMS) on stem cell differentiation to beta cells noted that by 2024, a case of autologous iPSC-derived islets achieving insulin independence at 1 year had been published — with 98% time-in-range glycemic control and 5% HbA1c — establishing proof-of-principle for stem cell-derived beta cell therapy even under immunosuppression constraints.[5]